Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Rapamycin, a specific inhibitor for mTOR complex 1, is an FDA-approved immunosuppressant for organ transplant. Recent developments have raised the prospect of using rapamycin to treat cancer or diabetes and to delay aging. It is therefore important to assess how rapamycin treatment affects glucose homeostasis. Here, we show that the same rapamycin treatment reported to extend mouse life span significantly impaired glucose homeostasis of aged mice. Moreover, rapamycin treatment of lean C57B/L6 mice reduced glucose-stimulated insulin secretion in vivo and ex vivo as well as the insulin content and beta cell mass of pancreatic islets. Confounding the diminished capacity for insulin release, rapamycin decreased insulin sensitivity. The multitude of rapamycin effects thus all lead to glucose intolerance. As our findings reveal that chronic rapamycin treatment could be diabetogenic, monitoring glucose homeostasis is crucial when using rapamycin as a therapeutic as well as experimental reagent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 3×
“[5] reported that rapamycin extends the median and maximal life span of both male and female mice and noted that “disease patterns of rapamycin-treated mice did not differ from those of control mice,” thereby raising the prospect of human clinical trials of rapamycin to treat aging and agerelated diseases [6, 7].”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 2×
“Recent studies suggest that rapamycin and its derivatives may be used as therapeutic agents for treating cancers, diabetes, and Alzheimer’s disease [3, 4].”
BackgroundNutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1
Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690
Phosphorylation of IRS proteins, insulin action, and insulin resistance
Boura-Halfon, S., & Zick, Y. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90437.2008 · Cited by 598 · cited 2×
“Binding of insulin to its tyrosine kinase receptor leads to the phosphorylation of the insulin receptor substrate (IRS) and the activation of the downstream PI3K/Akt kinase pathway as well as the mTOR signaling pathway to mediate insulin actions in liver and other tissues [2].”
BackgroundRecovery from diabetes in mice by β cell regeneration
Nir, T., Melton, D. A., & Dor, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32959 · Cited by 595 · cited 1×
“[33] have demonstrated the regenerative capacity of mouse pancreatic beta cells after diabetogenic injury, and they have also shown that immunosuppressants such as rapamycin and tarcolimus used in the Edmonton protocol, a pancreatic islet transplantation procedure for treating type I diabetes in patients, prevents bet…”
BackgroundFasting and Postchallenge Glycemia and Cardiovascular Disease Risk
Meigs, J. B., Nathan, D. M., D’Agostino, R. B., & Wilson, P. W. F. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1845 · Cited by 509 · cited 1×
“However, the potential side effects of rapamycin such as glucose intolerance—a significant risk factor for diabetes and cardiovascular diseases [8–11] as well as cognitive impairments [12]—warrant further investigation.”
BackgroundmTOR Complex1–S6K1 signaling: at the crossroads of obesity, diabetes and cancer
Dann, S. G., Selvaraj, A., & Thomas, G. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.04.002 · Cited by 481
Very Slow Turnover of β-Cells in Aged Adult Mice
Teta, M., Long, S. Y., Wartschow, L. M., Rankin, M. M., & Kushner, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2557 · Cited by 465 · cited 1×
“Next, we asked whether this rapamycin-induced glucose intolerance is age-dependent, given that the turnover rate of pancreatic beta cells in aged mice is slower [24].”
BackgroundHoude, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A. (2010) · Diabetes · doi:10.2337/db09-1324 · Cited by 456
The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man
Krebs, M., Brunmair, B., Brehm, A., Artwohl, M., Szendroedi, J., Nowotny, P., Roth, E., Fürnsinn, C., Promintzer, M., Anderwald, C., et al. (2007) · Diabetes · doi:10.2337/db06-1016 · Cited by 230
Cited by
The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging
Kennedy, B. K., & Lamming, D. W. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.009 · Cited by 544
Hartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
Late-life rapamycin treatment reverses age-related heart dysfunction
Flynn, J. M., O'Leary, M. N., Zambataro, C. A., Academia, E. C., Presley, M. P., Garrett, B. J., Zykovich, A., Mooney, S. D., Strong, R., Rosen, C. J., et al. (2013) · Aging Cell · doi:10.1111/acel.12109 · Cited by 311
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
Self-citationYang, S.-B., Tien, A.-C., Boddupalli, G., Xu, A. W., Jan, Y. N., & Jan, L. Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.043 · Cited by 242
“Because chronic systemic administration of rapamycin causes glucose intolerance and hypoinsulinemia (Yang et al., 2012), we infused rapamycin into the lateral ventricle in the brain through an osmotic pump to avoid potential complications of Neuron 75, 425–436, August 9, 2012 ª2012 Elsevier Inc.…”
MethodSelf-citation
Metadata
- Authors
- Yang, S.-B., Lee, H. Y., Young, D. M., Tien, A.-C., Rowson-Baldwin, A., Shu, Y. Y., Jan, Y. N., & Jan, L. Y.
- Venue
- Journal of Molecular Medicine
- Published
- 2011-11-22
- Volume
- 90
- Issue
- 5
- Pages
- 575-585
- ISSN
- 0946-2716 (ISSN-L)
- 1432-1440
- OpenAlex
- W1968341708
- Cited by
- 103
- References
- 10
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. https://app.cochat.ai/papers/10.1007/s00109-011-0834-3
- The paper
- Yang, S.-B., Lee, H. Y., Young, D. M., Tien, A.-C., Rowson-Baldwin, A., Shu, Y. Y., Jan, Y. N., & Jan, L. Y. (2012). Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. Journal of Molecular Medicine. https://doi.org/10.1007/s00109-011-0834-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.